Copper(i) targeting in the Alzheimer's disease context: a first example using the biocompatible PTA ligandElectronic supplementary information (ESI) available: UV-vis and EPR monitoring of CuII(Aβ) reduction by PTA, NMR spectra of Cu(i) exchange between Aβ and PTA, of O&z.dbd;PTA formation, HO&z.rad; production and ascorbate consumption studies, details of speciation calculations, large AFM pictures of aggregation study and description of materials and methods. See DOI: 10.1039/c5mt00077g

• Main Authors: Atrián-Blasco, E, Cerrada, E, Conte-Daban, A, Testemale, D, Faller, P, Laguna, M, Hureau, C
• Format: Journal Article
• Language: English
• Published: 05-08-2015
• ISSN: 1756-5901; 1756-591X
• DOI: 10.1039/c5mt00077g

Copper(
i
) coordinating ligands in the Alzheimer's disease context have remained unexplored, despite the biological relevance of this redox state of the copper ion. Here, we show that the PTA ligand can remove copper from Aβ, prevent reactive oxygen species production and oligomer formation, two deleterious events in the disease's etiology.
The use of a Cu(
i
) stabilizing ligand to target copper ions is a very promising approach against Alzheimer's disease.